



TECHNICAL BULLETIN

Bureau of Clinical Laboratories, Sharon P. Massingale, Ph.D., HCLD/CC (ABB) Director

September 24, 2018

Volume VIII Issue 2



ATTENTION: **NEWBORN SCREENING HEALTHCARE PROVIDERS**

The Bureau of Clinical Laboratories (BCL) will begin testing for Severe Combined Immunodeficiency Disorder (SCID) on October 1, 2018. SCID testing will be added to the panel of tests performed on all “first test” Newborn Screening specimens. SCID testing will be performed on “second test” specimens only if a valid result was not obtained on the first specimen or if a repeat specimen was requested.

Important Notes:

- SCID results will use gestational age as part of the testing algorithm. It will be crucial that the gestational age be recorded on the form in order to provide an accurate result.
- Premature infants may have multiple tests performed before a valid SCID result is obtained. The testing algorithm for SCID considers an abnormal result for a premature infant (<37 weeks gestational age) to be inconclusive. The abnormal result is more likely due to an immature immune system than SCID. The BCL will request that infants with an “Inconclusive (INCP)” result on their initial screen have a repeat collected every two weeks. The test should be repeated until a normal result is obtained or the infant’s adjusted gestational age is ≥ 37 weeks.

Alabama Department of Public Health
Bureau of Clinical Laboratories
P.O. Box 244018
8140 AUM Drive
Montgomery, AL 36024-4018

Phone: 334-260-3400
Fax: 334-260-3439
nbslab@adph.state.al.us